Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1-21. (Cancelled)

22. (Currently amended) A method for treating the formation, deposition, accumulation, or persistence of amyloid fibrils in a mammal, comprising the step of treating the fibrils with an effective amount of a procyanidin B2 ~~synthesized according to claim 1~~, wherein the effective amount is between about 0.1 mg/kg of body weight per day and about 1000 mg/kg of body weight of the mammal per day.

23. (Previously presented) The method of claim 22, wherein the amyloid fibrils are Aβ amyloid fibrils.

24. (Previously presented) The method of claim 22, wherein the amyloid fibrils are IAPP amyloid fibrils.

25-26. (Cancelled).

27. (Currently amended) A method for treating an amyloid disease ~~or a synucleinopathy~~ in a mammal, comprising the step of administering a therapeutically effective amount of a procyanidin B2 ~~synthesized according to claim 1~~ to the mammal wherein the effective amount is between about 0.1 mg/kg of body weight per day and about 1000 mg/kg of body weight per day.

28. (Previously presented) The method of claim 27, wherein the amyloid disease is a disease associated with the formation, deposition, accumulation, or persistence of an amyloid protein selected from the group consisting of Aβ amyloid, AA amyloid, AL amyloid, IAPP amyloid, α_2-microglobuli- n amyloid, transthyretin, prealbumin, and procalcitonin.

29. (Previously presented) The method of claim 28, wherein the amyloid disease is a disease associated with the formation, deposition, accumulation, or persistence of Aβ amyloid.

30. (Previously presented) The method of claim 28, wherein the amyloid disease is a disease associated with the formation, deposition, accumulation, or persistence of IAPP amyloid.

31. (Previously presented) The method of claim 27, wherein the amyloid disease is

selected from the group of diseases consisting of Alzheimer's disease, Down's syndrome, dementia pugilistica, multiple system atrophy, inclusion body myositosis, hereditary cerebral hemorrhage with amyloidosis of the Dutch type, Nieman-Pick disease type C, cerebral .beta.-amyloid angiopathy, dementia associated with cortical basal degeneration, the amyloidosis of type 2 diabetes, the amyloidosis of chronic inflammation, the amyloidosis of malignancy and Familial Mediterranean Fever, the amyloidosis of multiple myeloma and β-cell dyscrasias, the amyloidosis of the prion diseases, Creutzfeldt-Jakob disease, Gerstmann-Straussler syndrome, kuru, scrapie, the amyloidosis associated with carpal tunnel syndrome, senile cardiac amyloidosis, familial amyloidotic polyneuropathy, and the amyloidosis associated with endocrine tumors.

32. (Previously presented) The method of claim 31, wherein the amyloid disease is Alzheimer's disease.

33-36. (Cancelled)

37. (Withdrawn) The method of claim 27, wherein the mammal is a human.

38. (Cancelled).

39. (Previously presented) The method of claim 27, wherein the amount of the procyanidin B2 administered is between about 1 mg/kg of body weight per day and about 100 mg/kg of body weight per day.

40. (Previously presented) The method of claim 27, wherein the amount of the procyanidin B2 administered is between about 10 mg/kg of body weight per day and about 100 mg/kg of body weight per day.

41-59. (Cancelled).

60. (Currently amended) A pharmaceutical composition comprising: a) ~~a~~ procyanidin B2 ~~synthesized according to claim 1;~~ and b) a pharmaceutically acceptable ~~pharmaceutically acceptable~~ excipient, wherein the amount of procyanidin B2 in the composition is sufficient to deliver between about 1 mg/kg of body weight per day and about 1000 mg/kg of body weight per day to a mammal in a single dose.

61-95. (Cancelled)